ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib mesylate (IM), a specific inhibitor of BCR-ABL1 activity, causes a decrement of β-catenin expression, both in established cell lines and in primary cells derived from CML patients in blast crisis [18].